Stock Analysis on Net

Allergan PLC (NYSE:AGN)

$22.49

This company has been moved to the archive! The financial data has not been updated since May 7, 2020.

Economic Value Added (EVA)

Microsoft Excel

Economic Profit

Allergan PLC, economic profit calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2019 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


The financial performance from 2015 to 2019 is characterized by persistent economic value destruction, as evidenced by consistently negative economic profit. The organization failed to generate a positive spread between its operating returns and its cost of capital, resulting in a sustained inability to create economic value for shareholders.

Net Operating Profit After Taxes (NOPAT)
Operating profitability remained negative throughout the entire five-year observation period. A significant deterioration occurred in 2017, where NOPAT reached its lowest point at -10.55 billion US dollars. While there was a partial recovery in 2018 and 2019, the figures remained deeply negative, ending the period at -5.36 billion US dollars.
Invested Capital Trends
A consistent and substantial downward trend in invested capital is observed. The capital base declined from 127.50 billion US dollars in 2015 to 80.27 billion US dollars in 2019. This represents a continuous reduction in the total assets employed in the business, which served to mitigate the absolute magnitude of the annual capital charge.
Cost of Capital
The cost of capital exhibited moderate volatility, fluctuating within a range of 16.95% to 19.76%. After reaching a period low in 2017, the cost of capital trended upward, peaking at 19.76% in 2019. The relatively high cost of capital compounded the negative impact of the operating losses on the overall economic profit.
Economic Profit Analysis
Economic profit remained negative for all reported years, indicating that the company did not cover its cost of capital. The economic loss peaked in 2015 and 2017 at approximately -28 billion US dollars. By 2019, the economic profit improved slightly to -21.22 billion US dollars; however, this improvement was driven more by the significant reduction in the invested capital base than by an improvement in operational profitability.


Net Operating Profit after Taxes (NOPAT)

Allergan PLC, NOPAT calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Net income (loss) attributable to shareholders
Deferred income tax expense (benefit)1
Increase (decrease) in allowance for doubtful accounts2
Increase (decrease) in deferred revenue3
Increase (decrease) in accrued product warranties4
Increase (decrease) in restructuring reserve5
Increase (decrease) in equity equivalents6
Interest expense
Interest expense, operating lease liability7
Adjusted interest expense
Tax benefit of interest expense8
Adjusted interest expense, after taxes9
Interest income
Dividend income
Investment income, before taxes
Tax expense (benefit) of investment income10
Investment income, after taxes11
(Income) loss from discontinued operations, net of tax12
Net income (loss) attributable to noncontrolling interest
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in allowance for doubtful accounts.

3 Addition of increase (decrease) in deferred revenue.

4 Addition of increase (decrease) in accrued product warranties.

5 Addition of increase (decrease) in restructuring reserve.

6 Addition of increase (decrease) in equity equivalents to net income (loss) attributable to shareholders.

7 2019 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

8 2019 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 12.50% =

9 Addition of after taxes interest expense to net income (loss) attributable to shareholders.

10 2019 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 12.50% =

11 Elimination of after taxes investment income.

12 Elimination of discontinued operations.


Net Income (Loss) Attributable to Shareholders

The net income attributable to shareholders shows significant volatility over the observed period. Starting from approximately 3.9 billion US dollars at the end of 2015, it experienced a substantial increase to nearly 15 billion US dollars by the end of 2016. This peak was followed by a sharp reversal into negative territory, with losses amounting to approximately 4.1 billion US dollars in 2017. The negative trend continued in subsequent years, with losses deepening to around 5.1 billion and 5.3 billion US dollars in 2018 and 2019, respectively.

Net Operating Profit After Taxes (NOPAT)

The NOPAT metric also reflects a deteriorating operating performance over the period. It began in 2015 with a negative figure of about 3.5 billion US dollars, improved slightly in 2016 to approximately minus 2 billion US dollars, indicating a reduction in operating losses. However, in 2017, NOPAT deteriorated sharply, reaching a loss exceeding 10.5 billion US dollars. This was followed by some improvement yet continued negative results in 2018 and 2019, with losses of about 5.7 billion and 5.4 billion US dollars, respectively.

Overall Financial Trends

The company’s financial performance exhibits considerable instability over the five-year span. The marked peak in net income in 2016 appears anomalous given the general trend of losses in other years. Both net income and operating profitability suffer from large losses in recent years following the 2016 peak, suggesting potential challenges affecting operational efficiency and profitability after 2016.

The divergence between net income and NOPAT indicates that non-operating factors, such as one-time gains or losses, may have influenced net income, particularly in 2016. The sustained negative operating profit after taxes highlights fundamental operational difficulties that warrant further investigation.



Cash Operating Taxes

Allergan PLC, cash operating taxes calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Provision (benefit) for income taxes
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense
Less: Tax imposed on investment income
Cash operating taxes

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).


The data reveals significant fluctuations in the provision (benefit) for income taxes over the five years analyzed. Initially, there is a substantial tax benefit recorded, with the provision showing negative values each year from 2015 through 2018, indicating the company recognized income tax benefits rather than expenses during this period. The magnitude of the benefit peaks in 2017 with an amount exceeding -6.6 million US dollars, suggesting an extraordinary tax gain or adjustment that year. However, in 2019, this trend reverses, and the provision shifts to a positive value of approximately 146 thousand US dollars, reflecting a tax expense rather than a benefit.

In contrast, the cash operating taxes exhibit a more variable and less consistent pattern. The cash taxes paid decreased from about 398 thousand US dollars in 2015 to roughly 295 thousand in 2016 but then surged to approximately 1.24 million in 2017. This rise contrasts with the significant tax benefit recorded in the provision for the same year. A striking observation is seen in 2018 when the cash operating taxes turn negative, indicating a tax refund or credit of nearly 399 thousand US dollars. Following this, the cash taxes return to a positive figure of approximately 897 thousand US dollars in 2019.

Overall, the provision for income taxes and cash operating taxes demonstrate divergent movements during several years, which may indicate timing differences, adjustments, or tax strategy effects on reported versus actual cash tax payments. The large tax benefits recorded in provisions in earlier years, especially 2017, suggest one-time tax events or re-measurements impacting the income statement, while the cash operating taxes reflect the actual tax payments made or refunded, exhibiting a more volatile profile with a notable negative value in 2018.



Invested Capital

Allergan PLC, invested capital calculation (financing approach)

US$ in thousands

Microsoft Excel
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Current portion of long-term debt and capital leases
Long-term debt and capital leases, excluding current portion
Operating lease liability1
Total reported debt & leases
Shareholders’ equity
Net deferred tax (assets) liabilities2
Allowance for doubtful accounts3
Deferred revenue4
Accrued product warranties5
Restructuring reserve6
Equity equivalents7
Accumulated other comprehensive (income) loss, net of tax8
Noncontrolling interest
Adjusted shareholders’ equity
Construction in progress9
Marketable securities and other long-term investments10
Invested capital

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of allowance for doubtful accounts receivable.

4 Addition of deferred revenue.

5 Addition of accrued product warranties.

6 Addition of restructuring reserve.

7 Addition of equity equivalents to shareholders’ equity.

8 Removal of accumulated other comprehensive income.

9 Subtraction of construction in progress.

10 Subtraction of marketable securities and other long-term investments.


The financial data reveals several important trends over the five-year period ending December 31, 2019. The total reported debt and leases exhibit a consistent downward trajectory. Starting from approximately $42.89 billion in 2015, the debt decreases every year, reaching about $23.22 billion by the end of 2019. This represents a significant reduction in the company's leverage or obligations associated with debt and leases over the period.

Shareholders’ equity also demonstrates a declining pattern throughout these years. From $76.59 billion at the end of 2015, it slightly decreases to $76.19 billion in 2016 and continues this downward trend to $58.17 billion by 2019. This consistent reduction indicates possible challenges with retained earnings, equity issuance, or other comprehensive income affecting the equity base.

The invested capital, which encompasses the company's overall capital invested in operations, similarly shows a decreasing trend. Beginning at approximately $127.50 billion in 2015, invested capital reduces each year, culminating at about $80.27 billion in 2019. This decline suggests a potential shrinking scale of invested assets or capital employed, which could relate to asset divestitures, depreciation outpacing capital expenditure, or capital structure adjustments.

Total reported debt & leases
Substantial reduction by nearly 46% from 2015 to 2019, indicating active debt repayment or lease obligation reduction.
Shareholders’ equity
Gradual decline of roughly 24% over the period, possibly signaling diminished profitability, dividend distribution exceeding earnings, share repurchases, or adverse comprehensive income impacts.
Invested capital
Marked decrease of approximately 37%, reflecting either asset shrinkage, depreciation exceeding reinvestment, or strategic restructuring.

In summary, all three key financial measures present downward trends, with debt levels showing the most pronounced reduction, followed by invested capital and shareholders’ equity. The data implies an overall contraction in the scale of the business's financial operations and capitalization, alongside a strategic effort to reduce leverage.


Cost of Capital

Allergan PLC, cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Preferred shares, $0.0001 par value per share (book value) ÷ = × =
Long-term debt and capital leases, including current portion3 ÷ = × × (1 – 12.50%) =
Operating lease liability4 ÷ = × × (1 – 12.50%) =
Total:

Based on: 10-K (reporting date: 2019-12-31).

1 US$ in thousands

2 Equity. See details »

3 Long-term debt and capital leases, including current portion. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Preferred shares, $0.0001 par value per share (book value) ÷ = × =
Long-term debt and capital leases, including current portion3 ÷ = × × (1 – 12.50%) =
Operating lease liability4 ÷ = × × (1 – 12.50%) =
Total:

Based on: 10-K (reporting date: 2018-12-31).

1 US$ in thousands

2 Equity. See details »

3 Long-term debt and capital leases, including current portion. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Preferred shares, $0.0001 par value per share (book value) ÷ = × =
Long-term debt and capital leases, including current portion3 ÷ = × × (1 – 12.50%) =
Operating lease liability4 ÷ = × × (1 – 12.50%) =
Total:

Based on: 10-K (reporting date: 2017-12-31).

1 US$ in thousands

2 Equity. See details »

3 Long-term debt and capital leases, including current portion. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Preferred shares, $0.0001 par value per share (book value) ÷ = × =
Long-term debt and capital leases, including current portion3 ÷ = × × (1 – 12.50%) =
Operating lease liability4 ÷ = × × (1 – 12.50%) =
Total:

Based on: 10-K (reporting date: 2016-12-31).

1 US$ in thousands

2 Equity. See details »

3 Long-term debt and capital leases, including current portion. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Preferred shares, $0.0001 par value per share (book value) ÷ = × =
Long-term debt and capital leases, including current portion3 ÷ = × × (1 – 12.50%) =
Operating lease liability4 ÷ = × × (1 – 12.50%) =
Total:

Based on: 10-K (reporting date: 2015-12-31).

1 US$ in thousands

2 Equity. See details »

3 Long-term debt and capital leases, including current portion. See details »

4 Operating lease liability. See details »


Economic Spread Ratio

Allergan PLC, economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data (US$ in thousands)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).

1 Economic profit. See details »

2 Invested capital. See details »

3 2019 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


The financial data indicates a persistent inability to generate positive economic value over the five-year period from 2015 to 2019. The company consistently reported negative economic profit and a negative economic spread ratio, signifying that the returns on invested capital remained below the required cost of capital throughout the entire observation window.

Invested Capital Trends
A consistent and significant reduction in invested capital is observed. The capital base decreased from 127.5 billion US dollars in 2015 to 80.3 billion US dollars by 2019. This steady downward trajectory suggests a strategic contraction of the asset base or a systematic repayment of capital over the analyzed period.
Economic Profit Analysis
Economic profit remained negative across all five years, indicating a failure to create shareholder value in absolute terms. While the deficit fluctuated—reaching a low of approximately 28.3 billion US dollars in 2015 and seeing a temporary increase in losses in 2017—there was a general trend toward reducing the annual economic loss, ending at 21.2 billion US dollars in 2019.
Economic Spread Ratio Interpretation
The economic spread ratio remained volatile and firmly in negative territory, ranging from a high of -20.64% in 2016 to a low of -27.14% in 2017. The persistence of these negative percentages confirms that the company did not achieve a positive spread between its return on invested capital and its cost of capital, thereby eroding economic value consistently over the five-year duration.

Economic Profit Margin

Allergan PLC, economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data (US$ in thousands)
Economic profit1
 
Net revenues
Add: Increase (decrease) in deferred revenue
Adjusted net revenues
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).

1 Economic profit. See details »

2 2019 Calculation
Economic profit margin = 100 × Economic profit ÷ Adjusted net revenues
= 100 × ÷ =

3 Click competitor name to see calculations.


The financial performance from December 31, 2015, to December 31, 2019, is characterized by consistently negative economic profit and margins, although a gradual trend toward recovery is observable over the five-year period.

Economic Profit Trends
Economic profit remained in negative territory throughout the analyzed period, indicating that the company did not generate returns above its cost of capital. The most significant deficit occurred in 2015 at 28.36 billion US dollars. Despite a secondary spike in losses in 2017, there was a sustained reduction in the economic deficit from 2018 onward, concluding at 21.22 billion US dollars in 2019.
Adjusted Net Revenue Performance
Adjusted net revenues demonstrated stability with modest growth. Following a slight decline in 2016, revenues recovered and trended upward, increasing from 15.06 billion US dollars in 2015 to 16.08 billion US dollars by the end of 2019. This indicates a stable top-line foundation despite the underlying economic losses.
Economic Profit Margin Analysis
The economic profit margin was deeply negative throughout the period, reflecting a substantial gap between operating returns and the required return on capital. A positive trajectory is noted as the margin improved from -188.25% in 2015 to -131.97% in 2019. This narrowing of the negative margin suggests an incremental improvement in the efficiency of capital utilization relative to revenue generation.